anbenitamab

1. 01:55
   x.com

   In patients with HER2-positive advanced #breastcancer, the HER2-targeted bispecific antibody #anbenitamab plus albumin-bound docetaxel led to 24-month progression-free survival of

1. 17:21
   x.com

   🔥Impressive results!
2. 17:08
   x.com

   #ESMO26 | Anbenitamab + HB1801
3. 16:22
   x.com

   Anbenitamab plus HB1801 . Her2 targeting Bispecific antibody from China and aluminum bound docetaxel vs THP . PFS HR 0.46 . Published in @nejm . Needle in Her2 positive is moving
4. 16:04
   x.com

   HEALER: anbenitamab + HB1801 vs THP in HER2+ BC.
5. 15:58
   x.com

   Binghe Xu presents data from the Healer trial in China evaluating anbenitamab (bispecific HER2ab) with lipo docetaxel vs THP for HER2+ MBC showing marked improvement in PFS and mod
6. 15:53
   x.com

   Anbenitamab + HB1801 has better PFS than THP as first line therapy (control arm did poorly 14.3 mos)
7. 15:52
   x.com

   Oral abstract #BreastCancer session at #ESMO26: very promising data with the bispecific anti-HER2 antibody #anbenitamab plus an experimental taxane #HB1801 as first-line therapy in
8. 15:52
   x.com
9. 14:35
   x.com

   Presented at #ESMO26:
10. 14:30
    nejm.org

    Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer
11. 06:41
    x.com

    #ESMO26 | Anbenitamab – Phase III

1. 22:26
   x.com

   Anbenitamab plus chemotherapy for previously treated HER2-positive GC/GEJC: Updated OS analysis of KC-WISE 🇨🇳

Heat now 67·Peak in the comparable set 100 (Oct 24 18:00)·Change over 24h in the comparable set +884%·Participants now 12

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.